No conviction changes recorded
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
16.3%/yr
±3.9% · revenue growth to justify current price
FCF-Based Reverse DCF
13.8%/yr
±3.1% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~6h).
Eagle will generate this view by the next trading session (~6h).
Q1 FY2026 record: $669M sales (+9%), ATS segment +20% organic driven by semiconductor capex. AI computing driving dispense and x-ray demand. fPE 21.8x fair but not cheap. 16% analyst upside to $312. C...
NDSN Q1: ATS accelerating 20.7% organic in semiconductor/electronics dispense. IPS margins pressured by mix. Strong operating leverage and cash generation. Riding AI/semi capex cycle. Valuation: 31x T...